APA (7th ed.) Citation

Matsubara, N., Yonese, J., Kojima, T., Azuma, H., Matsumoto, H., Powles, T., . . . Yamashiro, M. (2023). Japanese subgroup analysis of EV‐301: An open‐label, randomized phase 3 study to evaluate enfortumab vedotin versus chemotherapy in subjects with previously treated locally advanced or metastatic urothelial carcinoma. Cancer medicine (Malden, MA), 12(3), 2761-2771. https://doi.org/10.1002/cam4.5165

Chicago Style (17th ed.) Citation

Matsubara, Nobuaki, et al. "Japanese Subgroup Analysis of EV‐301: An Open‐label, Randomized Phase 3 Study to Evaluate Enfortumab Vedotin Versus Chemotherapy in Subjects with Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma." Cancer Medicine (Malden, MA) 12, no. 3 (2023): 2761-2771. https://doi.org/10.1002/cam4.5165.

MLA (9th ed.) Citation

Matsubara, Nobuaki, et al. "Japanese Subgroup Analysis of EV‐301: An Open‐label, Randomized Phase 3 Study to Evaluate Enfortumab Vedotin Versus Chemotherapy in Subjects with Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma." Cancer Medicine (Malden, MA), vol. 12, no. 3, 2023, pp. 2761-2771, https://doi.org/10.1002/cam4.5165.